23andMe identifies how genetics can influence risks for certain diseases and if you are a carrier of inherited conditions such as breast cancer and Parkinson’s disease.
This information can then be used to help carriers be aware of conditions that they may pass on to children, so they can be closely monitored, or even to make changes to their own lives.
23andMe recently dominated headlines after revealing exclusive a four-year collaboration with pharmaceutical colossus GlaxoSmithKline (GSK) for customer data to help the latter discover drug targets.
Various news outlets speculate the business is currently worth $1.8bn. There is no news on a stock market flotation, but this is certainly a name to keep watching. (LMJ)
It may not be a household name, but cybersecurity firm Darktrace is now worth $1.65bn – not bad for a five-year-old firm.
It uses machine learning and artificial intelligence tools to alert customers when their systems have been infiltrated.
Its software learns the patterns of normal behaviour inside a computer network, so it can spot anomalies when they occur and stop problems from escalating into a crisis. The downside for investors is that it has no current plans to float on the stock market. (DC)
Digital health business Babylon Health is aiming to reduce the strain on healthcare services by helping people interpret symptoms via its artificial intelligence and direct them to a human doctor if medical care is needed.
The company also connects patients with doctors via phone calls or video chat on their mobile, so they can receive medical advice and potentially a prescription.
Babylon currently has operations in the UK and Rwanda, but plans to expand into China, the US, Canada and the Middle East. (LMJ)